

DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration Rockville, MD 20857

April 5, 2004

Robert W. Pollock Vice President Lachman Consultant Services, Inc. 1600 Stewart Avenue Westbury, NY 11590

Dear Mr. Pollock:

Your petition requesting the Food and Drug Administration to determine whether Zoloft (sertraline hydrochloride) Tablets 150 mg and 200 mg (NDA-19-839) have been voluntarily withdrawn or withheld for sale for safety or effectiveness reasons was received by this office on 04/5/2004. It was assigned docket number 2004P-0162/CP 1 and it was filed on 04/5/2004. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Lyle D. Jaffe
Division of Dockets Management
Office of Management Programs
Office of Management